{"id":"https://openalex.org/W4399668402","doi":"https://doi.org/10.1200/jco.2024.42.16_suppl.2604","title":"Examining response to immunotherapy in clear-cell renal cell carcinoma using baseline serum metabolic signatures.","display_name":"Examining response to immunotherapy in clear-cell renal cell carcinoma using baseline serum metabolic signatures.","publication_year":2024,"publication_date":"2024-06-01","ids":{"openalex":"https://openalex.org/W4399668402","doi":"https://doi.org/10.1200/jco.2024.42.16_suppl.2604"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2024.42.16_suppl.2604","doi":"https://doi.org/10.1200/jco.2024.42.16_suppl.2604","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1200/jco.2024.42.16_suppl.2604","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5024974658","display_name":"Leila Pirhaji","orcid":"https://orcid.org/0009-0008-7023-0430","observed_orcids":["https://orcid.org/0009-0008-7023-0430"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Leila Pirhaji","raw_affiliation_strings":["Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cambridge, MA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013842049","display_name":"Matthew Morris","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Matthew Morris","raw_affiliation_strings":["ReviveMed Inc., Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ReviveMed Inc., Cambridge, MA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027399095","display_name":"Jonah A. Eaton","orcid":"https://orcid.org/0000-0002-3229-4686","observed_orcids":["https://orcid.org/0000-0002-3229-4686"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jonah Eaton","raw_affiliation_strings":["ReviveMed Inc., Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ReviveMed Inc., Cambridge, MA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5100574425","display_name":"Min Zhang","orcid":"https://orcid.org/0009-0004-4883-8379","observed_orcids":["https://orcid.org/0009-0004-4883-8379"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Min Zhang","raw_affiliation_strings":["ReviveMed Inc., Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ReviveMed Inc., Cambridge, MA","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"42","issue":"16_suppl","first_page":"2604","last_page":"2604"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10836","display_name":"Metabolomics and Mass Spectrometry Studies","score":0.4343000054359436,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10836","display_name":"Metabolomics and Mass Spectrometry Studies","score":0.4343000054359436,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10449","display_name":"Renal cell carcinoma treatment","score":0.2919999957084656,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.19009999930858612,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/clear-cell-renal-cell-carcinoma","display_name":"clear cell renal cell carcinoma","score":0.9779999852180481},{"id":"https://openalex.org/keywords/immunotherapy-response-prediction","display_name":"immunotherapy response prediction","score":0.7879999876022339},{"id":"https://openalex.org/keywords/immune-checkpoint-blockade","display_name":"immune checkpoint blockade","score":0.9100000262260437},{"id":"https://openalex.org/keywords/anti-pd-1-antibody","display_name":"anti-PD-1","score":0.8960000276565552},{"id":"https://openalex.org/keywords/mtor-inhibition","display_name":"mTOR inhibition","score":0.8690000176429749},{"id":"https://openalex.org/keywords/untargeted-metabolomics","display_name":"untargeted metabolomics","score":0.7860000133514404},{"id":"https://openalex.org/keywords/metabolic-signatures","display_name":"metabolic signatures","score":0.6930000185966492},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.8199999928474426},{"id":"https://openalex.org/keywords/prognostic-factors","display_name":"prognostic factors","score":0.7540000081062317},{"id":"https://openalex.org/keywords/liquid-chromatography-mass-spectrometry","display_name":"liquid chromatography-mass spectrometry","score":0.6620000004768372},{"id":"https://openalex.org/keywords/batch-effect-correction","display_name":"batch effect correction","score":0.5640000104904175}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8770632147789001},{"id":"https://openalex.org/C2777472916","wikidata":"https://www.wikidata.org/wiki/Q1164529","display_name":"Renal cell carcinoma","level":2,"score":0.7155181765556335},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.6183679699897766},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.48322948813438416},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.47697529196739197},{"id":"https://openalex.org/C2781278892","wikidata":"https://www.wikidata.org/wiki/Q18556340","display_name":"Clear cell renal cell carcinoma","level":3,"score":0.44584619998931885},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3384193181991577},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.3361924886703491},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3339884281158447}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2024.42.16_suppl.2604","doi":"https://doi.org/10.1200/jco.2024.42.16_suppl.2604","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1200/jco.2024.42.16_suppl.2604","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9940000176429749}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4407701494","https://openalex.org/W4413409002","https://openalex.org/W4389043947","https://openalex.org/W4295007859","https://openalex.org/W4308769925","https://openalex.org/W4404065663","https://openalex.org/W7124895060","https://openalex.org/W4220964513","https://openalex.org/W4414306062","https://openalex.org/W4324094506"],"abstract_inverted_index":{"2604":[0],"Background:":[1],"Clear":[2],"cell":[3,5],"renal":[4],"carcinoma":[6],"(ccRCC)":[7],"accounts":[8],"for":[9,190,226,383],"80%":[10],"of":[11,51,81,134,165,181,252,315,324,339,357,370],"kidney":[12],"cancer":[13],"cases.":[14],"While":[15],"immune":[16],"checkpoint":[17],"blockade":[18],"(ICB)":[19],"is":[20],"a":[21,69,117,223,250,263,321,380],"front-line":[22],"treatment,":[23],"most":[24],"patients":[25,98,359],"do":[26],"not":[27],"have":[28,66,140,286],"durable":[29],"clinical":[30,186,191,206,306],"benefit,":[31],"and":[32,90,103,111,156,169,172,195,262,326,348,364,387],"current":[33],"biomarkers":[34],"fail":[35],"to":[36,46,61,124,177,204,230,246,275,285,373],"predict":[37,205,361],"response.":[38],"Previous":[39],"studies":[40],"reported":[41],"metabolic":[42,57,355,368],"alterations":[43],"in":[44,75,99,120,132,143,244,308,331],"response":[45,60,245,363,372],"ICB":[47,62,310,374],"based":[48],"on":[49],"profiling":[50],"202":[52],"targeted":[53,145],"metabolites.":[54],"To":[55],"identify":[56,231],"signatures":[58,369],"predicting":[59,371],"at":[63,84,375],"baseline,":[64],"we":[65,219,298],"developed":[67,200],"mzLearn,":[68],"data-driven":[70],"algorithm":[71],"that":[72],"overcomes":[73],"obstacles":[74],"liquid":[76],"chromatography/mass":[77],"spectrometry":[78],"(LC/MS)":[79],"measurements":[80],"untargeted":[82,227],"metabolomics":[83],"scale.":[85],"Methods:":[86],"We":[87,159,198,235,248,352],"used":[88,220],"baseline":[89,166,301,354],"post-treatment":[91],"raw":[92],"LC/MS":[93],"data":[94],"(n=1,650)":[95],"from":[96,272],"ccRCC":[97,358],"Phase":[100,104,334],"I":[101,335],"(n=91)":[102],"III":[105],"(n=741)":[106],"trials":[107],"(Workbench":[108],"IDs":[109],"ST001236":[110],"ST001237),":[112],"where":[113],"anti-PD-1":[114,253,273],"treatment":[115,362],"yielded":[116],"significant":[118,270],"increase":[119],"overall":[121],"survival":[122,216],"compared":[123],"mTOR":[125,276,290],"inhibitor.":[126],"mzLearn":[127],"detected":[128],"4,018":[129],"signals":[130,139],"present":[131],">60%":[133],"all":[135],"samples.":[136],"The":[137],"identified":[138,236,249,299],"90%":[141],"accuracy":[142],"detecting":[144],"metabolites":[146],"with":[147,185,212,241,256,305,320,345],"10%":[148],"false":[149],"positives":[150],"while":[151],"effectively":[152],"overcoming":[153],"signal":[154],"drifts":[155],"batch":[157],"effects.":[158],"then":[160,199],"performed":[161],"unsupervised":[162],"K-means":[163],"clustering":[164],"metabolomic":[167,228,239],"features":[168,183,303,317,341],"supervised":[170,296],"linear":[171],"Cox":[173],"proportional":[174],"hazard":[175],"models":[176,203],"find":[178],"minimal":[179],"subsets":[180],"those":[182],"associated":[184,304],"benefit":[187,207,307],"after":[188,289,391],"adjusting":[189],"variables,":[192],"e.g.,":[193],"age":[194],"prognostic":[196],"scores.":[197],"logistic":[201],"regression":[202],"(CB),":[208],"i.e.,":[209],"tumor":[210],"shrinkage":[211],"\u22656":[213],"months":[214],"progression-free":[215],"(PFS).":[217],"Finally,":[218],"PIUMet":[221,337],"(1),":[222],"network-based":[224],"tool":[225],"analysis,":[229],"linked":[232],"mechanisms.":[233],"Results:":[234],"three":[237],"main":[238],"subtypes":[240],"distinct":[242],"PFS":[243,259,288],"treatments.":[247],"cluster":[251,265],"responders":[254],"(n=279)":[255],"significantly":[257],"higher":[258,287],"(p=2e-5,":[260],"HR=0.56)":[261],"non-responder":[264],"(n=261)":[266],"who":[267],"showed":[268,353],"no":[269],"effect":[271],"relative":[274],"inhibition":[277,291],"(p=0.874,":[278],"HR=1.02).":[279],"Importantly,":[280],"one":[281],"subtype":[282],"(n=201)":[283],"tended":[284],"(p=0.11,":[292],"HR=1.27).":[293],"Next,":[294],"using":[295],"methods,":[297],"97":[300],"metabolite":[302],"the":[309,327,332],"arm.":[311],"A":[312],"smaller":[313],"subset":[314],"top-scoring":[316],"predicts":[318],"CB":[319],"cross-validated":[322],"AUC":[323],"78%":[325],"AUC=71%":[328],"when":[329],"tested":[330],"independent":[333],"cohort.":[336],"analysis":[338],"these":[340],"predicted":[342],"their":[343],"association":[344],"sphingolipid":[346],"metabolism":[347],"arginine/proline":[349],"metabolism.":[350],"Conclusions:":[351],"stratification":[356],"can":[360],"discovered":[365],"novel":[366],"blood-based":[367],"baseline.":[376],"These":[377],"results":[378],"establish":[379],"solid":[381],"foundation":[382],"predictive":[384],"biomarker":[385],"discovery":[386],"potentially":[388],"therapeutic":[389],"recommendations":[390],"further":[392],"validation.":[393],"1.":[394],"Pirhaji":[395],"et":[396],"al.":[397],"Nat.":[398],"Met.":[399],"2016.":[400]},"counts_by_year":[],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2024-06-15T00:00:00"}